Artiva Biotherapeutics (ARTV) Treasury Shares (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Treasury Shares data on file, last reported at $4.1 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $4.1 million, up 176.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (up 176.39% YoY), and the FY2025 annual result was $2.6 million, up 421.07% from the prior year.
• Treasury Shares advanced to $4.1 million in Q1 2026 per ARTV's latest filing, from $2.6 million in the prior quarter.
• Over five years, Treasury Shares peaked at $4.1 million in Q1 2026 and troughed at $22514.0 in Q4 2023.
• A 4-year average of $1.6 million and a median of $1.4 million in 2025 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2024 and 2026: Treasury Shares surged 2151.24% in 2024, then soared 176.39% in 2026.
• A 4-year view of Treasury Shares shows it stood at $22514.0 in 2023, then surged by 2151.24% to $506845.0 in 2024, then jumped by 421.07% to $2.6 million in 2025, then surged by 53.73% to $4.1 million in 2026.
• Business Quant data shows ARTV's Treasury Shares at $4.1 million in Q1 2026, $2.6 million in Q4 2025, and $1.3 million in Q3 2025.